{"id":13111,"date":"2021-01-19T07:43:26","date_gmt":"2021-01-19T07:43:26","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=13111"},"modified":"2022-08-04T02:36:06","modified_gmt":"2022-08-04T02:36:06","slug":"prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/","title":{"rendered":"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform"},"content":{"rendered":"\n<p>Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer acute myeloid leukemia (AML); solid tumours including breast, ovarian and gastric cancers; and glioblastoma multiforme, the aggressive brain cancer.<\/p>\n\n\n\n<p>Prescient\u2019s OmniCAR technology represents a step up from the current chimeric antigen receptor T-cell (CAR T) therapy, a form of&nbsp;<a href=\"#\">immunotherapy that involves modifying a patient\u2019s white blood cells so they recognise and kill cancer<\/a>&nbsp;cells.<\/p>\n\n\n\n<p>An American woman, Laurie Adami,&nbsp;<a href=\"#\">recently told Stockhead<\/a>&nbsp;how CAR T therapy saved her life by curing her stage IV follicular non-Hodgkin lymphoma.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer acute myeloid leukemia (AML); solid tumours including breast, ovarian and gastric cancers; and glioblastoma multiforme, the aggressive brain cancer. Prescient\u2019s OmniCAR technology represents a step up from the current chimeric antigen receptor T-cell (CAR T) therapy, a form of&nbsp;immunotherapy that [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":27160,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,1],"tags":[29],"class_list":["post-13111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-news","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform - PTX Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer acute myeloid leukemia (AML); solid tumours including breast, ovarian and gastric cancers; and glioblastoma multiforme, the aggressive brain cancer. Prescient\u2019s OmniCAR technology represents a step up from the current chimeric antigen receptor T-cell (CAR T) therapy, a form of&nbsp;immunotherapy that [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T07:43:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-04T02:36:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"enouvoteam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"enouvoteam\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/\"},\"author\":{\"name\":\"enouvoteam\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"headline\":\"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform\",\"datePublished\":\"2021-01-19T07:43:26+00:00\",\"dateModified\":\"2022-08-04T02:36:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/\"},\"wordCount\":111,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Articles\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/\",\"name\":\"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg\",\"datePublished\":\"2021-01-19T07:43:26+00:00\",\"dateModified\":\"2022-08-04T02:36:06+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg\",\"width\":640,\"height\":360,\"caption\":\"Chimeric Antigen Receptor (CAR) binds to a membrane surface protein on a cancer cell\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\",\"name\":\"enouvoteam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"caption\":\"enouvoteam\"},\"sameAs\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\"],\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform - PTX Therapeutics","og_description":"Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer acute myeloid leukemia (AML); solid tumours including breast, ovarian and gastric cancers; and glioblastoma multiforme, the aggressive brain cancer. Prescient\u2019s OmniCAR technology represents a step up from the current chimeric antigen receptor T-cell (CAR T) therapy, a form of&nbsp;immunotherapy that [&hellip;]","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/","og_site_name":"PTX Therapeutics","article_published_time":"2021-01-19T07:43:26+00:00","article_modified_time":"2022-08-04T02:36:06+00:00","og_image":[{"width":640,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg","type":"image\/jpeg"}],"author":"enouvoteam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"enouvoteam"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/"},"author":{"name":"enouvoteam","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"headline":"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform","datePublished":"2021-01-19T07:43:26+00:00","dateModified":"2022-08-04T02:36:06+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/"},"wordCount":111,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg","keywords":["Prescient Therapeutics"],"articleSection":["Articles","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/","name":"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg","datePublished":"2021-01-19T07:43:26+00:00","dateModified":"2022-08-04T02:36:06+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/01\/GettyImages-1033017906-640x360-1.jpg","width":640,"height":360,"caption":"Chimeric Antigen Receptor (CAR) binds to a membrane surface protein on a cancer cell"},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c","name":"enouvoteam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","caption":"enouvoteam"},"sameAs":["https:\/\/template.reachmarkets.com.au\/investorportal"],"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/13111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=13111"}],"version-history":[{"count":1,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/13111\/revisions"}],"predecessor-version":[{"id":27161,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/13111\/revisions\/27161"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/27160"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=13111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=13111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=13111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}